Beqvez shows long-term safety, efficacy in adults with hemophilia B

Beqvez shows long-term safety, efficacy in adults with hemophilia B

Beqvez (fidanacogene elaparvovec-dzkt), a one-time gene therapy developed by Pfizer that was formerly approved for hemophilia B, was found to be safe and effective in reducing bleeding episodes and the need for factor replacement therapy in a small group of men. That’s according to results from a long-term Phase 2 trial (NCT03307980), which followed 14 adult men with severe or moderately severe hemophilia B for up to six years. “These results of…